Search

Aim: Tall stature, defined as a height greater than 2 standard deviation score (SDS), affects 2.3% of children. Our study aimed to explore the causes of tall stature in children and assess the long-term outcomes for these cases. Materials and Methods: This study included 393 children with tall stature who applied to a pediatric endocrinology clinic between 2015-2024. The patients’ medical histories, physical examinations, laboratory findings and hormonal profiles were recorded. Results: Two hundred and forty-seven girls (62.8%) and 146 boys (37.2%) with a mean age of 9.0±2.8 (0.7-16.8) years were included. The majority of the cases presented with obesity and tall stature (25.2%), early onset of puberty signs and tall stature (18.8%), and early onset of puberty signs (12%). Tall stature was not reported as a complaint in 32.7% of the patients. At the initial visit, the height SDS was 2.6±0.5 (2.0-6.2), the mid parenteral height (MPH) SDS was 0.1±0.8 [(-1.9)-3.6] and the predicted adult height (PAH)-MPH was 8.5±7.8 [(-8.5)-39.0] cm. Considering their diagnoses, the majority were familial tall stature (39.9%), obesity + tall stature (32.3%), and central precocious puberty (13.5%). Cranial imaging was performed in 33 cases, and pathology was detected in 10. 95 of the cases had reached their final height. There was a statistically significant difference between the final height SDS and the patients’ initial height SDS and MPH SDS values (p

Aim: Central precocious puberty (CPP) is the development of secondary sex characteristics before the age of 8 years in girls and 9 years in boys due to premature activation of the hypothalamic–pituitary–gonadal (HPG) axis. The aim of this study was to investigate the long-term pubertal data and height of girls treated with leuprolide acetate for CPP.Materials and Methods: A total of 70 girls followed up and treated for CPP between December 2002 and June 2013 were included in the study. Medical history, physical examination findings, maternal/paternal height, midparental height (MPH), laboratory and radiological findings, and weight, height, and body mass index (BMI) before and at end of treatment were recorded from the patients’ records. Age at menarche, menstrual regularity, and final height/BMI were determined in post-treatment follow-up.Results: The mean duration of leuprolide acetate therapy was 21.73±8.45 months, MPH was 158.3±4.5 cm, predicted adult height was 157.7±7.4 cm, and final height was 161.3±6.7 cm. Final height was moderately correlated with height-for-age at presentation (r=0.443, p

Copyright of Namık Kemal Tıp Dergisi is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)